By Jennifer Chiou
New York, Sept. 20 - Barclays Bank plc priced $9.82 million of 7.5% yield optimization notes with contingent protection due Sept. 22, 2011 linked to the common stock of Pfizer Inc., according to a 424B2 filing with the Securities and Exchange Commission.
Interest is payable monthly.
Each note has a face value of $17.16, which is equal to the closing price of Pfizer stock on the pricing date.
The payout at maturity will be par unless the final price of Pfizer stock is less than 80% of the initial share price, in which case the payout will be one share of Pfizer stock.
UBS Financial Services Inc. and Barclays Capital Inc. are the underwriters.
| Issuer: | Barclays Bank plc
|
| Issue: | Yield optimization notes with contingent protection
|
| Underlying stock: | Pfizer Inc. (Symbol: PFE)
|
| Amount: | $9,819,930.12
|
| Maturity: | Sept. 22, 2011
|
| Coupon: | 7.5%, payable monthly
|
| Price: | Par of $17.16
|
| Payout at maturity: | If final share price is less than trigger price, one Pfizer share; otherwise, par
|
| Initial share price: | $17.16
|
| Trigger price: | $13.73, 80% of initial price
|
| Pricing date: | Sept. 16
|
| Settlement date: | Sept. 21
|
| Underwriters: | UBS Financial Services Inc. and Barclays Capital Inc.
|
| Fees: | 2%
|
| Cusip: | 06740L212
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
